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The calcium ionophore properties of A23187 and of two lysophosphatidic acid (LPA) analogs 
(I-palmitoyl- and 1-hexadecyl-sn-glycero-3-phosphate or P-GPA and H-GPA, respectively) were 
compared using platelet membrane vesicles loaded with 45Ca. Half maximal effect (HME) was obtained 
at 5 PM and 10 PM for H-GPA and P-GPA, respectively, against 0.7 PM for A23187, which released 2 
times more Ca. The three compounds also induced platelet aggregation with a HME at 0.5 PM, 0.3 PM 
and 0.01 ,uM for A23187, P-GPA and H-GPA, respectively. The clear dissociation between the two effects 
appearing for both LPA raises some doubt about the general idea that (lyso) PA participate in cell 
activation through their calcium ionophore properties. 
Platelet Aggregation Activation Calcium Lysophosphatidic acid Ether phospholipid 
1. INTRODUCTION 
An increased turnover of inositol phospholipids 
upon specific cell stimulation has been recognized 
as a widespread biochemical event [l-6]. The so 
called ‘phosphatidylinositol effect’ follows the ac- 
tivation of a specific phospholipase C, leading to 
the formation of diglycerides, which are used for 
phosphatidylinositol resynthesis via phosphatidic 
acid (PA) and phosphatidyl-CMP (CDP- 
diglyceride) [l-6]. The transient accumulation of 
PA occurring under these conditions might be in- 
volved in the mechanism of cell activation by pro- 
moting an increased level of cytoplasmic calcium, 
owing to the calcium ionophore properties of this 
phospholipid [7-l 11. Such a role is further sup- 
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phatidic acid; P-GPA, I-palmitoyl-sn-glycero-3-phos- 
phate; H-GPA, 1-hexadecyl-sn-glycero-3-phosphate; 
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ported by the observation that PA is able to evoke 
physiological responses upon addition to various 
intact cells [8,12-141. 
Lysophosphatidic acid (LPA) was also detected 
in stimulated platelets, which might involve either 
a diglyceride lipase coupled to a monoglyceride 
kinase [ 151, or a PA-specific phospholipase AZ 
[ 16,171. This more polar lysophospholipid carries 
calcium ionophore properties [ 181 and is able to 
promote platelet aggregation [ 18-231, to poten- 
tiate arachidonic acid release from thrombin- 
treated platelets [24] and to enhance neutrophil 
chemotaxis [25]. As such, it offers a useful model 
to study the properties of PA on intact cells. In this 
respect a 1-alkyl derivative of LPA revealed 30 
times more potent than its 1-acyl-analog in induc- 
ing human platelet aggregation [23]. This was 
recently confirmed with acetal-PA [26]. We here 
show that both 1-alkyl-LPA and 1-acyl-LPA 
display similar potency in releasing calcium from a 
platelet membrane fraction and that, at a variance 
with calcium ionophore A23187, no relationship 
exists between their ability to activate platelets and 
their calcium gating properties. 
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2. MATERIALS AND METHODS 
45Calcium chloride (4-50 Ci/g Ca) was purchas- 
ed from the Radio~hemic~ Centre (Amersham). 
Calcium ionophore A23 187 was obtained from 
Boehringer (Mannheim), whereas 1 -palmitoyl-sn- 
glycero-3-phosphate (P-GPA) was from Serdary 
(London, Ontario); I-hexadecyl-sn-glycero-3-phos- 
phate (H-GPA) was prepared as in [23]. 
2.1. Determination of calcium release from 
platelet membranes 
Platelet concentrates prepared from healthy 
human volunteer donors were obtained from the 
Blood Transfusion Centre and were used within 
18 h after blood collection. Platelets were isolated 
and washed as in [27]. Cells from one concentrate 
were suspended in 10 ml of ice-cold lysis buffer 
(pH 7.0) containing 30 mM Hepes, 30 mM KCI, 
2.5 mM MgClz and IO mM potassium oxalate. 
Cells were lysed at 4°C using the nitrogen cavita- 
tion procedure after equilibration for 20 min 
under 70 bars [28]. After a centrifugation at 
13 000 x g for 10 min, the resulting supernatant 
was centrifuged at 40000 x g for 60 min at 4°C. 
The peIlet was suspended in a minimal volume of 
lysis buffer and protein concentration was ad- 
justed to 1.5 mg/mi as determined in 1291. One 
volume of platelet membranes was added to 9 vol. 
of incubation buffer (pH 7.0) containing 100 mM 
KCI, 2.5 mM MgC12, 30 mM Hepes, 2 mM ATP, 
1 mM potassium oxalate and 0.01 mM 45CaClt. 
Incubation was performed at 37°C under shaking 
for various periods of time. At 30 min various 
agents were added under a minimal volume of sol- 
vent (0.01 ml/ml). Solvents were dimethylsulfox- 
ide for A23187 and ethanol for LPA. The same 
volume of solvent was added in control samples, 
with identical results for dimethylsulfoxide and for 
ethanol. 
At various times of the incubation procedure, 
0.5-ml aliquots were removed and filtered through 
a millipore sampIing unit using 0.5pm pore size 
filters. Filters were air dried, sofubilized in 10 ml 
aquasol and counted in an Interte~hnique liquid 
spectrometer (model SL 4000) equipped with an 
automatic quenching collector. 
2.2. Determination of platelet aggregation 
Platelet aggregation was determined as in [23] by 
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the turbidimetric method in [30], using platelets 
isolated from fresh human blood as in [31]. 
3. RESULTS 
As shown in fig. 1, platelet membranes were able 
to take up actively calcium upon incubation in a 
medium containing 45CaC12, ATP and potassium 
oxalate. Under these conditions calcium uptake 
Ievelled off at 30 min and the amount of incor- 
porated radioactivity remained stable upon longer 
incubation. Further addition of A23187 to the in- 
cubation mixture 30 min after commencement of 
the uptake assay was followed by a rapid Ioss of 
caicium from the membranes. This was almost 
complete 20 min later and clearly illustrates the 
calcium ionophore properties of the drug. Under 
the same conditions, both kinds of LPA also in- 
duced some release of entrapped calcium, as in [ 181 
for I-acyl-LPA, 
More quantitative data about the relative poten- 
cies of the 3 compounds toward platelet mem- 
branes are given in fig.2. A23187 appeared as the 
most powerful calcium ionophore, able to release 
50% of calcium within 10 min at 5 PM final con- 
centration, whereas 10 FM H-CPA and 50 PM P- 
GPA reieased only 25% of calcium under the same 
conditions. Higher concentrations gave somewhat 
Fig.1. Calcium uptake by platelet membranes and 
release induced by ionophores. Results indicate the 
radioactivity remaining on the filters during uptake and 
after addition at 30 min of dimethylsulfoxide (I), 
I-alkyl-LPA (2), I-acyl-LPA (3) and A23187 (4). This 
experiment is representative of 3 similar experiments. 
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lower values, which still remains difficult to ex- 
plain. From data of fig.2, it was found that half 
maximal effect (HME) was obtained at 0.7 PM, 
5 PM and 10rM with A23187, H-GPA and P- 
GPA, respectively. 
Fig.2 also compares the platelet aggregating pro- 
perties of the 3 compounds. A clear dissociation 
appeared between calcium release and platelet ag- 
gregation induced by H-GPA, whereas the two 
dose-response curves were more closely related in 
bp 
I c I 
72 I P r,j’ IO’ 1.5’ 16’ M 
Fig.2. Comparative potency of A23187 and LPA 
towards platelet aggregation and calcium release from 
platelet membranes. Platelet aggregation i duced by 
various concentrations of A23187 (A), 1-acyl-LPA (B) 
and 1-alkyl-LPA (C) is expressed as the percentage of
maximal response. For calcium release, the 3 
compounds were added 30 min after loading the 
membranes with 45Ca nd the incubation was carried out 
for 10 min more. Percentage of release was calculated by 
plotting the decrease of membrane radioactivity 
compared to control membranes v.s the total 
radioactivity remaining in control membranes. (A) 
Aggregation; (A) calcium release. Each value is the 
mean of 2-6 different determinations. 
the case of A23187. Under the same conditions, P- 
GPA displayed an intermediary picture. The con- 
centrations of H-GPA, P-GPA and A23187 giving 
a full aggregation response were 0.1 /cM, 5 PM and 
0.5 PM, respectively. The same concentrations 
added to platelet membranes released O%, 10% 
and 10% of calcium within 10 min. Also, relative 
to platelet aggregation, HME was reached at 
0.5 PM, 0.3 PM and 0.01 FM for A23187, P-GPA 
and H-GPA, respectively. 
4. DISCUSSION 
The ‘40000 x g fraction’ used here represents a
mixed membrane fraction containing both surface 
membrane and intracellular membrane elements 
[32-351. As shown in [36], the membranes taking 
up calcium might correspond to vesicular struc- 
tures originating from the dense tubular system, 
although the contribution of inside-out resealed 
vesicles from the surface membrane cannot be 
definitely ruled out (Levy-Toledano, S. et al., per- 
sonal communication). 
Our results indicate that no clear relationship ex- 
ists between calcium gating properties and 
physiological effects of LPA. This is specially evi- 
dent for H-GPA. A generally accepted hypothesis 
is that calcium ionophores like LPA trigger platelet 
activation by mobilizing calcium from intracellular 
stores, presumably the dense tubular system [18]. 
One could thus expect that the more stable l-alkyl- 
LPA would be able to reach its intracellular target 
more easily than LPA carrying a 1-acyl-group 
susceptible to hydrolysis by intracellular 
lysophospholipase [37,38]. However, we did not 
find evidence for a significant breakdown of 
l-[3H]stearoyl-LPA upon incubation with human 
platelets (unpublished). 
Another explanation might be that platelet ag- 
gregation induced by LPA does not involve their 
calcium ionophore properties. In this respect, 
authors in [39] observed that platelet shape change 
and secretion induced by thrombin can occur in the 
absence of any increase of cytoplasmic free 
calcium level and they suggested the existence of 
calcium-independent pathways leading to platelet 
activation. 
It is now well established that platelet stimulation 
by thrombin leads to the phosphorylation of two 
proteins displaying M, values in the range of 20000 
117 
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and 40000 [40,41]. The so called 20-kDa protein 
corresponds to myosin light chain and is 
phosphorylated through a calcium-calmodulin- 
dependent process [42], whereas the 40-kDa pro- 
tein is the substrate of the calcium-activated 
phospholipid-dependent protein kinase C [43]. 
Authors in [44] could recently dissociate these two 
events, since 20-kDa protein phosphorylation was 
specifically triggered by A23187, whereas the syn- 
thetic diglyceride 1-oleoyl-2-acetyl-glycerol pro- 
moted the selective phosphorylation of the 40-kDa 
protein in intact human platelets. So in the latter 
case, no calcium mobilization occurred despite a 
large conversion of the diglyceride into its cor- 
responding phosphatidate. 
In conclusion, our results fit rather well with the 
scheme proposed by Nishizuka’s group and call for 
another explanation concerning the role of 
phosphatidic acid in the mechanism of stimulus- 
activation coupling. 
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